UBS Group
VIVS

UBS Group’s VivoSim Labs VIVS Stock Holding History

UBS Group’s Portfolio VIVS Stock Details VIVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-19
Closed -$16K – 8904
2015
Q1 		$16K Sell
19
-67
-78% -$92.5K ﹤0.01% 7230
2014
Q4 		$150K Buy
+86
New +$132K ﹤0.01% 5305

Other funds holding VIVS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.81B AUM 32.31% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

UBS Group's VIVS Position: Q2 2026 in Review

UBS Group reduced its VivoSim Labs (VIVS) stake by 98% in Q2 2026, selling an estimated $1.25K and leaving 18 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #10279.

UBS Group first reported a position in VIVS in Q4 2014 and has held it in 47 quarters since. The position peaked at $4.1M in Q1 2017. 26 funds tracked by Wall St. Rank hold VIVS as of Q2 2026.

  • UBS Group held 18 shares of VivoSim Labs worth $20 as of Q2 2026.
  • UBS Group sold 934 VivoSim Labs shares in Q2 2026, an estimated $1.25K.
  • VivoSim Labs made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10279 holding.
  • UBS Group first reported a position in VivoSim Labs in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's VivoSim Labs position peaked at $4.1M in Q1 2017.
  • 26 funds tracked by Wall St. Rank held VivoSim Labs as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.